A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 [EMBARQ-CSU LTE] (NCT07256392)

CDX0159-17

This trial is Coming soon
Registration number NCT07256392
The purpose of this extension study is to collect long-term efficacy and safety data on barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who completed the treatment and follow-up periods of the Phase 3 clinical trials. This study will also fulfill the Celldex commitment to provide post-trial access to participants who have completed the phase 3 studies, where applicable.

Program & service

This trial is being run with the Specialty Medicine service, and as part of the Dermatology program.

Trial phase

Phase 3

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Prof Johannes S Kern

Key inclusion data

MUST have successfully completed the preceding phase 3 clinical trials (CDX0159-12 or CDX0159-13). NO NEW PARTICIPANTS ARE ABLE TO BE RECRUITED FOR THIS STUDY.

More information

To find out more about this clinical trial, please review full details on the ANZCTR website.

View on ANZCTR

If you would like further details or have any questions about this clinical trial, we encourage you to get in touch with us and a member of our team will be happy to provide you with more information.